Weight loss drugs targeting GLP-1 receptors like Zepbound and Wegovy are popular, but other companies offer innovative alternatives. Zealand Pharma's petrelintide activates amylin and calcitonin receptors, potentially providing better outcomes than GLP-1 drugs.